Eisai files for full FDA approval for Alzheimer's drug Leqembi

FILE PHOTO: The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo

(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug Leqembi, which was recently approved under the agency’s accelerated review process.

Source: Read Full Article